GSK CTO, Boehringer Exec On The Metaverse And Pharma’s Foot In The Door

GSK Has Seen ' Lot Of Success' With Bots

Big pharma executives discuss the transformative potential of the metaverse in the life sciences segment and how things are shaping in the virtual world amid the hype. GSK’s senior VP and chief technology officer outlines to Scrip gains made deploying digital twins and bots.

L to R: Ram Deshpande, partner, digital transformation, EY; Agam Upadhyay, senior VP, Chief Technology Officer, GSK USA and Philippe Houben, head, GTM and digital transformation, IMETA , Boehringer Ingelheim

As the metaverse, the next iteration of the internet that encompasses and converges virtual reality (VR) and physical reality in the digital space, promises to change the experience of stakeholders across the healthcare sector, pharma appears keen to be part of what could be the next big thing.

Metaverse And The Emotional Dimension

The BioAsia conclave also heard Philippe Houben, Boehringer Ingelheim's head of Go-to-market and digital transformation, IMETA [India, Middle East, Turkey, Africa], discuss the opportunity the metaverse provides to drive an emotional connect with patients and caregivers.

“What I am fundamentally seeing is a difference when we talk about metaverse is the virtual reality - that is allowing experience not with the brain, but with your heart, an engagement with someone like if you are physically present,” Houben declared at a session moderated by Ram Deshpande, partner, digital transformation, at EY.

Houben expects a 'huge difference' in the way industry can engage with patients or the caregiver by bringing them through that immersive experience.

“We are experimenting [with] this and we do see a huge impact of bringing that emotional dimension within the way we are engaging with the patient. So it's a technology that is enabling those kinds of engagements; that emotional dimension is to me the game changer from a technology perspective,” the BI executive said.

Houben explained that patients don't always understand their disease progression and that could, among other reasons, impact adherence to treatments; similarly caregivers too may not understand these critical aspects.'De-mystifying' disease progression is important.

While industry has typically thus far tried to explain things using graphs or testimonials of patients, “the metaverse could allow us to experiment - how will disease progression impact my daily life?; it also allows us to explain that better to physicians and other caregivers”.

He reiterated the role of the emotional dimension, “because I would say it's much more powerful than explaining something to someone - let them experience it”.

In areas like mental health, the metaverse can potentially provide an environment where you can feel safe, because you're somewhat anonymous. “So there are some very specific use cases where the patient will see the benefit not to be physically in front of a human but to have a safe environment; besides distances [to access appropriate care/treatment] in India and a lot of emerging markets is a huge topic,” he said.

While, VR, augmented reality (AR) and mixed reality have been deployed over the years to treat mental health disorders, there are concerns, on the flip side, that excessive time spent in 3D immersive games as in social media could itself lead to addiction, anxiety etc.

Last year, an article in General Psychiatry noted that living in a world within the metaverse could potentially lead to the worsening of specific mental health disorders, though with the anonymity of the virtual realm, more individuals may feel comfortable sharing their stories with professionals and others facing similar issues. “Hence, this rapidly expanding technology could significantly improve access to mental healthcare, especially given the present acute shortage of mental health professionals,” the authors Usmani SS, Sharath M and Mehendale M said.

The metaverse has impressive potential for many segments of society, but only time will reveal how its future unfolds, they added

Senior executives from big pharma signaled at the recent BioAsia conference, how industry is moving when it comes to the metaverse, though the field is still evolving and a long road lies ahead

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

More from Scrip

Stock Watch: Market Optimism Outshines Q1 Currency And Tariff Woes

 
• By 

The weak US dollar helped some companies reporting first-quarter results and hindered others reporting in stronger currencies. But even the impacts of currencies and Medicare modernization on first-quarter revenues were overlooked when an end to the trade wars seemed possible.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.

In Brief: Strong OS Results For Immutep’s Eftilagimod/Keytruda Combo In Head And Neck Cancer

 

Australian firm's combo of eftilagimod and Keytruda shows 17.6-month median overall survival in first-line HNSCC patients with low PD-L1, raising hopes for potential accelerated approval.